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2Department of Medicine, University of Kentucky College of Medicine, Lexington, KY, USA
3Departments of Biostatistics and Statistics, University of Kentucky College of Public Health, 
Lexington, KY, USA
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SUMMARY
Several pathogens have been associated with increased cardiovascular disease (CVD) risk. 
Whether this occurs with Mycobacterium tuberculosis infection is unclear. We assessed if 
tuberculosis disease increased the risk of acute myocardial infarction (AMI). We identified 
patients with tuberculosis index claims from a large de-identified database of ~15 million adults 
enrolled in a U.S. commercial insurance policy between 2008 and 2010. Tuberculosis patients 
were 1:1 matched to patients without tuberculosis claims using propensity scores. We compared 
the occurrence of index AMI claims between the tuberculosis and non-tuberculosis cohorts using 
Kaplan–Meier curves and Cox Proportional Hazard models. Data on 2026 patients with 
tuberculosis and 2026 propensity-matched patients without tuberculosis were included. AMI was 
more frequent in the tuberculosis cohort compared with the non-tuberculosis cohort, 67 (3·3%) vs. 
32 (1·6%) AMI cases, respectively, P < 0·01. Tuberculosis was associated with an increased risk of 
AMI (adjusted hazard ratio (HR) 1·98, 95% confidence intervals (CI) 1·3–3·0). The results were 
similar when the analysis was restricted to pulmonary tuberculosis (adjusted HR 2·43, 95% CI 
1·5–4·1). Tuberculosis was associated with an increased risk of AMI. CVD risk assessment should 
be considered in tuberculosis patients. Mechanistic studies of tuberculosis and CVD are warranted.
*Author for correspondence: M. A. Huaman, Division of Infectious Diseases, University of Cincinnati, 231 Albert Sabin Way, 
Cincinnati, OH 45267, USA. (moises.huaman@uc.edu). 
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INTRODUCTION
The burden of tuberculosis and cardiovascular disease (CVD) is enormous worldwide [1, 2]. 
Tuberculosis and CVD may not only occur concomitantly, but also affect the risk of one 
another. Potential contributors to CVD risk in tuberculosis may include a direct effect of 
Mycobacterium tuberculosis on the myocardium and coronary arteries, increased immune 
activation and cytokine production, and cross-reactivity of anti-mycobacterial antibodies 
against cardiovascular tissue [3].
We used a registry of ~15 million persons enrolled in a U.S. commercial insurance policy 
representing 1 284 681 prescribers and 3631 health care provider designations from all 
geographic U.S. regions [4], to determine whether tuberculosis increased the risk of acute 
myocardial infarction (AMI) after adjusting for traditional CVD risk factors.
METHODS
We identified patients with and without an index tuberculosis disease claim (International 
Classification of Diseases, ninth revision (ICD-9) codes, 010·0–018·9) between 2008 and 
2010. We included patients aged 25 years or older who had complete administrative data. 
Younger patients were excluded due to much lesser likelihood of AMI occurrences. We 
excluded patients with human immunodeficiency virus (HIV)/AIDS (acquired immune 
deficiency syndrome) claims (ICD-9 code, 042) and organ or tissue transplantation claims 
(ICD-9 codes, V42·0–V42·9) as both tuberculosis and AMI could manifest very differently 
in these populations. Tuberculosis patients were required not to have a tuberculosis claim the 
year prior, to improve likelihood of selection for new tuberculosis diagnoses within the study 
period. Patients with claims related to latent tuberculosis infection (ICD-9 codes, 795·5, 
795·51, 795·52) and/or non-tuberculous mycobacterial infections (ICD-9 codes, 030·0–
031·9) were excluded from the study.
We then identified patients without tuberculosis claims to establish a comparison cohort. We 
used propensity scores for 1:1 matching of tuberculosis and non-tuberculosis patients based 
on the nearest neighbor method with a caliper width set at 0·2 [5]. To calculate propensity 
scores, we included candidate risk factors for both tuberculosis and AMI. Thus, propensity 
scores were created through a logistic regression for the predicted probability of having a 
tuberculosis claim as a function of birth year, sex, race, hypertension (ICD-9 codes, 401·0–
401·9), diabetes (ICD-9 codes, 250·0–250·9), hyperlipidemia (ICD-9 codes, 272·0–272·9), 
obesity (ICD-9 codes, 270·0–270·9), tobacco use (ICD-9 code, 305·1), chronic kidney 
disease (ICD-9 code, 585·9) and major autoimmune condition which included ICD-9 codes 
for systemic lupus erythematosus (710·0), rheumatoid arthritis and other inflammatory 
polyarthropathies (714·0–714·9), psoriasis (696·0–696·8), Crohn’s disease (555·0–555·9), 
and ulcerative colitis (556·0–556·9).
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We set the date of index tuberculosis claim as the start date for each tuberculosis and non-
tuberculosis-matched pair, and looked for the occurrence of index AMI claims (ICD-9 
codes, 410·0–410·9) within the following year period. Thus patients were followed through 
to the date of index AMI claim, death, insurance disenrollment or completion of 1-year 
period, whichever happened first. Dates available in the study database included information 
on month and year therefore we rounded all dates to the first day of their corresponding 
month and year. To better assess the timing of index AMI claim in relation to the index 
tuberculosis claim, we excluded those pairs where an AMI index claim was first reported 
within the same month of the index tuberculosis claim. Patients with an index AMI claim 
were required not to have an AMI claim the year prior to their follow-up start date, to 
improve likelihood of selection for new AMI diagnoses within the study period.
Baseline characteristics of the matched cohorts were compared using χ2 tests to ensure there 
were no residual significant differences. We used the Kaplan–Meier method to estimate the 
proportion of patients free of AMI over time. The log-rank test was used to compare 
differences in AMI between cohorts. Cox Proportional Hazards models for paired data were 
used to assess tuberculosis as a risk factor for AMI after adjusting for the other risk factors. 
The results of Cox models were presented as hazard ratios (HR) accompanied by 95% 
confidence intervals (CI). All analyses were performed using Stata software (version 12·0; 
StataCorp, Texas, USA) with P < 0·05 as the level of statistical significance. This project 
was exempt of institutional review board review as it involved the analysis of available, 
existing, de-identified data.
RESULTS
Data on 2026 patients with tuberculosis and 2026 propensity score-matched patients without 
tuberculosis were included in the study. There were no significant differences between the 
tuberculosis and non-tuberculosis cohorts in terms of age ⩾65 years (56·9% vs. 57·3%, 
P=0·78), male sex (43·7% vs. 43·5%, P = 0·89), black race (17·7% vs. 17·3%, P= 0·74); 
Hispanic ethnicity (3·9% vs. 4·2%, P = 0·63), diabetes mellitus (50·3% vs. 50·5%, P = 0·88), 
hypertension (65·3% vs. 64·7%, P = 0·72), hyperlipidemia (56·3% vs. 55·9%, P = 0·83), 
obesity (16·2% vs. 15·2%, P = 0·34), tobacco use (17·3% vs. 17·8%, P = 0·65), chronic 
kidney disease (16·9% vs. 16·7%, P = 0·87), or major autoimmune disease (19·8% vs. 
19·6%, P = 0·87), indicating sufficient propensity score matching.
There were more cases of AMI in the tuberculosis cohort (67 cases, 3·3%) than the non-
tuberculosis cohort (32 cases, 1·6%), P < 0·01. The Kaplan–Meier survival curves are shown 
in Figure 1 (log-rank test, P < 0·01). The risk of developing AMI in patients with 
tuberculosis claims was higher compared with patients without tuberculosis claims and 
similar baseline characteristics and comorbidities (adjusted HR 1·98, 95% CI 1·3–3·0). The 
proportional hazards assumption was not violated based on the Schoenfeld residuals test, P = 
0·25. The results were similar when the analysis was restricted to pulmonary tuberculosis 
claims (adjusted HR 2·43, 95% CI 1·5–4·1). Hypertension (adjusted HR 1·91, 95% CI 1·1–
3·6), chronic kidney disease (adjusted HR 2·68, 95% CI 1·7–4·2), and tobacco use (adjusted 
HR 1·6, 95% CI 1·1–2·6) were independently associated with AMI.
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DISCUSSION
In this propensity score-matched analysis of commercially insured U.S. patients with 
multiple comorbidities, we showed that tuberculosis disease was associated with an 
approximate twofold increased risk of AMI by 1 year after a tuberculosis disease index 
claim. Similar results were obtained when the analysis was restricted to pulmonary 
tuberculosis.
Our findings are consistent with a large population-based retrospective cohort study 
conducted in Taiwan which showed a 1·4-fold increased subsequent risk of acute coronary 
syndrome (ACS), a composite outcome that includes unstable angina and AMI diagnoses, 
among patients with a history of tuberculosis disease [6]. The Taiwan study showed higher 
incidence rate ratios of ACS between tuberculosis and non-tuberculosis patients when 
comorbidities such as hypertension, diabetes, or hyperlipidemia were present. Therefore, we 
reason that our higher risk estimate may be explained by the overall higher frequency of 
traditional CVD risk factors in our population as compared with the Taiwan study. In 
addition, the Taiwan study looked at ACS, whereas we focused our analysis on AMI only. 
Notably, a similar analysis of the Taiwan national registry showed a 1·5-fold increased risk 
of ischemic stroke among persons with a history of tuberculosis [7], which indicates that the 
effect of tuberculosis in atherosclerotic disease goes beyond coronary heart disease. A major 
strength of our study was the use of propensity score matching to control for demographics 
and available information on relevant comorbidities among patients with and without 
tuberculosis, allowing a more accurate analysis of the relationship between tuberculosis and 
AMI.
Numerous intracellular pathogens that establish chronic and/or latent infection have been 
implicated in the development of CVD; i.e. HIV, cytomegalovirus, and Chlamydia 
pneumoniae [8]. The connection between infection and CVD centers on several mechanisms 
including direct cellular infection and damage, increased immune activation, or induction of 
autoimmunity [9]. Atherogenesis and plaque rupture are, in part, dependent on the role of 
activated monocytes/macrophages and Th1 effector cells releasing interferon-γ, 
interleukin-1, and other cytokines [10]. Patients with tuberculosis share this pro-
inflammatory profile of activated monocyte/macrophages, T cells and elevated inflammatory 
cytokines [3]. Tuberculosis may also induce autoimmunity through molecular mimicry of 
the heat shock protein (HSP) system. Antibodies to mycobacterial HSP65 may cross-react 
with human HSP60, as studies indicate that antibodies to HSP65 correlate with the 
development of atherosclerosis [11]. Cases of sudden cardiac death and arteritis suggested a 
direct effect of M. tuberculosis on the myocardium and coronary arteries but these seem to 
be rare occurrences [12].
There are a number of factors that may affect the conclusions of this study. We could not 
obtain detailed information on the length of time or severity of comorbidities such as 
hypertension, diabetes, renal disease, or autoimmune disorders, which could affect the risk 
of AMI differently. Quantification of tobacco use or body mass index for each patient was 
not available. However, we captured diagnostic codes for tobacco use and obesity as proxies. 
This database has been used for analyses of fungal and mycobacterial infections including 
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tuberculosis showing patterns consistent with what has been reported in the literature [4]. 
However, because tuberculosis is managed at local U.S. health departments, we could not 
further confirm tuberculosis diagnoses or access anti-tuberculosis treatment data for our 
study population. Most tuberculosis patients included in the study would be expected to be 
taking anti-tuberculosis medications within a year of their first tuberculosis insurance claim. 
This could be of importance, as rifamycin-containing regimens could decrease the 
effectiveness of drugs used to treat traditional CVD risk factors such as hypertension, 
diabetes and hyperlipidemia, and thereby increase the risk of AMI. The incidence of AMI in 
the non-tuberculosis group (1·6%) was 1·5–2 times higher than the expected incidence of 
AMI in a U.S. population with similar age and sex distribution [13]. This suggests that some 
of the AMI events extracted from the study registry could have been prevalent cases; or that 
our study population was at an overall higher risk for CVD than the general population, as 
suggested by the presence of multiple comorbidities in our population. As with all 
administrative databases there may be significant biases and/or errors in coding and 
reporting though we have no reason to suspect they would be channeled in one direction or 
another. Finally, it is important to mention that our results are not necessarily generalizable 
to uninsured populations or settings where tuberculosis is highly endemic. Since the 
prevalence of CVD and CVD risk factors is rising globally, research is greatly needed to 
determine whether tuberculosis would have a similar effect over AMI in populations that are 
traditionally more vulnerable to tuberculosis (i.e. homeless individuals, intravenous drug 
users, alcohol users, persons who live in poverty and resource-constraint settings).
In conclusion, tuberculosis was associated with an approximate twofold increased risk of 
AMI in this commercially insured U.S. population with multiple comorbidities. These 
findings suggest that CVD assessment should be considered in tuberculosis patients. Our 
results need further validation in longitudinal studies that control for CVD risk factors in 
greater detail. Further mechanistic studies of tuberculosis and CVD are warranted.
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Fig. 1. 
Kaplan–Meier curves for acute myocardial infarction in the study groups.
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